Old age is associated with a progressive decline of mitochondrial function. According to the publication Dr. Peleg and co-authors [MBO Rep. 2016 Mar;17(3):455-69], fruitflies Drosophila melanogaster, contrary to common assumptions, increase oxygen consumption as they reach midlife. Midlife flies show changes in the metabolome, particularly, elevated acetyl-CoA levels. ATP citrate lyase is the primary enzyme responsible for the synthesis of cytosolic acetyl-CoA in many tissues. Authors decreased the activity of the acetyl-CoA-synthesizing enzyme ATP citrate lyase (ATPCL) and found that this targeted intervention both alleviate the observed aging-associated changes and promote longevity. This finding reveals a pathway that couples changes of intermediate metabolism during aging with the changes in the activity of associated enzymes that modulate organismal life span. So it could be possible to develop drugs which are able to extend the life span through inhibition of ATP citrate lyase.
Our company suggests development of the compounds, which will inhibit ATP citrate lyase in human cells. We suggest multi-step strategy, involving virtual screening, high-throughput screening, in silico drug design, ADME/Tox and pharmacokinetics optimization and other preclinical development of clinical trials candidate compounds. If you choose our investment project, you will be able to get income of 1 - 2 mln. usd. (estimated cost of clinical trials candidate) in around 2-3 years of preclinical drug development.